Retinoblastoma Service, Royal London Hospital, London, England2Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, England3University College London Institute of Ophthalmology, London, England.
Retinoblastoma Service, Royal London Hospital, London, England.
JAMA Ophthalmol. 2015 Dec;133(12):1455-8. doi: 10.1001/jamaophthalmol.2015.2861.
Anterior chamber seeding following intraophthalmic artery chemotherapy is rarely reported.
To describe clinicopathologic observations in eyes in which intraophthalmic artery chemotherapy for retinoblastoma failed and to report anterior chamber involvement.
A retrospective case series of 12 enucleated eyes (11 patients) with retinoblastoma refractory to intraophthalmic artery chemotherapy between March 1, 2010, and October 31, 2013, at University College London Institute of Ophthalmology and the Retinoblastoma Service, Royal London Hospital. Data analysis was conducted from June 1, 2014, to March 1, 2015. The International Classification of Retinoblastoma groups were B in 1 eye (8%), C in 4 eyes (33%), and D in 7 eyes (58%). Systemic chemotherapy with vincristine sulfate, etoposide, and carboplatin had failed in 10 patients (91%) and 6 eyes (50%) received additional local treatments. In 6 eyes (50%) anterior chamber invasion was clinically detectable. On histopathologic examination, 4 eyes (33%) had no viable retinal tumor; the remainder had poorly differentiated tumor (6 eyes [50%]) or moderately differentiated tumor (2 eyes [17%]). Anterior segment involvement occurred in the ciliary body and/or ciliary muscle (7 eyes [58%]), iris (6 eyes [50%]), and cornea (4 eyes [33%]).
Intraophthalmic artery chemotherapy can fail in eyes with retinoblastoma. In contrast to previous reports on outcomes following intraophthalmic artery chemotherapy, our series shows involvement of the anterior segment of the eye, including the ciliary body, iris, and cornea. Careful case selection and follow-up are advised.
眼内动脉化疗后前房播散很少见。
描述眼内动脉化疗治疗视网膜母细胞瘤失败的临床病理观察,并报告前房受累情况。
2010 年 3 月 1 日至 2013 年 10 月 31 日期间,伦敦大学学院眼科研究所和伦敦皇家医院视网膜母细胞瘤服务中心对 12 只(11 例)眼进行了回顾性病例系列研究,这些眼对眼内动脉化疗有抗药性。数据分析于 2014 年 6 月 1 日至 2015 年 3 月 1 日进行。国际视网膜母细胞瘤分类为 B 组 1 眼(8%)、C 组 4 眼(33%)和 D 组 7 眼(58%)。10 例患者(91%)全身性化疗失败(硫酸长春新碱、依托泊苷和卡铂),6 只眼(50%)接受了额外的局部治疗。6 只眼(50%)临床上可检测到前房侵犯。组织病理学检查发现,4 只眼(33%)无存活的视网膜肿瘤;其余 6 只眼(50%)为低分化肿瘤,2 只眼(17%)为中分化肿瘤。前节受累发生在睫状体和/或睫状体肌(7 只眼[58%])、虹膜(6 只眼[50%])和角膜(4 只眼[33%])。
眼内动脉化疗可能在患有视网膜母细胞瘤的眼中失败。与之前关于眼内动脉化疗后结果的报告不同,我们的系列研究显示眼睛的前节包括睫状体、虹膜和角膜均有受累。建议仔细选择病例并进行随访。